Onametostat (JNJ-64619178; JNJ64619178) is a novel, potent, selective and pseudo-irreversible PRMT5 (protein arginine methyltransferase 5) inhibitor with potential anticancer activity.

WDR5-0103 is a small molecule that binds a peptide-binding pocket on WDR5 (Kd = 450 nM), inhibiting the catalytic activity of the MLL core complex in vitro (IC50 = 39 µM).

EPZ004777 (EPZ-004777) is a potent and selective inhibitor of DOT1 Like Histone Lysine Methyltransferase (DOT1L) inhibitor with antineoplastic activity.

HLCL-61 hydrochloride is a potent, selective, first-in-class small-molecule inhibitor of PRMT5 (protein arginine methyltransferase) that has the potential for treatment of acute myeloid leukemia.

JQ-EZ-05 (also abbreviated as JQEZ5) is a novel, potent, specific and reversible inhibitor of EZH2 (overexpressed in tumor cells such as lung cancer).

CM-272 (CM272) is a first-in-class, reversible, and dual inhibitor of G9a and DNMTs in hematological malignancies with antineoplastic effects.

EPZ020411 (EPZ-020411) HCl, the hydrochloride salt of EPZ020411, is a novel and selective inhibitor of PRMT6 (protein arginine methyltransferase, IC50 =10 nM) with therapeutic utility in the treatment of cancer.

EPZ011989 (EPZ-011989) is a potent, orally bioavailable EZH2 inhibitor with high anticancer activity.

AZ-505 (AZ505) 2TFA, the ditrifluoroacetate salt of AZ-505, is an SMYD2 (SET and MYND domain-containing protein 2) inhibitor with anticancer activity.

SGC707 (SGC-707) is a novel, cell-permeable and allosteric PRMT3 inhibitor (protein arginine methyltransferase 3 inhibitor) with potential anticancer activity.